Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brivestobart
- Development stage
- Phase 2
- Lead developer
- Guangzhou Gloria Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GLS-012 (brivestobart) is a monoclonal antibody that targets the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), functioning as an immune checkpoint inhibitor. By blocking LAG-3, GLS-012 aims to enhance T-cell activation and restore antitumor immune responses, making it a potential therapy for various malignancies. It is being developed primarily for the treatment of advanced solid tumors, including non-small cell lung cancer and melanoma. The drug is administered intravenously and has shown acceptable toxicity with preliminary antitumor activity in early-phase clinical trials. GLS-012 is under development by Guangzhou Gloria Biosciences[1][2][3][4][7].
- Other names
- brivestobart
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on brivestobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brivestobart.